Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years

GSK Investigational Site, Pittsburgh

GSK Investigational Site, Grove City

GSK Investigational Site, Washington D.C.

GSK Investigational Site, Norfolk

GSK Investigational Site, Winston-Salem

GSK Investigational Site, Raleigh

GSK Investigational Site, Hickory

GSK Investigational Site, Melbourne

GSK Investigational Site, Pembroke Pines

GSK Investigational Site, Miami

GSK Investigational Site, Tampa

GSK Investigational Site, Huntsville

GSK Investigational Site, Bristol

GSK Investigational Site, Knoxville

GSK Investigational Site, Bardstown

GSK Investigational Site, South Bend

GSK Investigational Site, Richland

GSK Investigational Site, Bismarck

GSK Investigational Site, Peoria

GSK Investigational Site, St Louis

GSK Investigational Site, Kansas City

GSK Investigational Site, North Platte

GSK Investigational Site, Alliance

GSK Investigational Site, Little Rock

GSK Investigational Site, Oklahoma City

GSK Investigational Site, Houston

GSK Investigational Site, Colorado Springs

GSK Investigational Site, Pueblo

GSK Investigational Site, Boise

GSK Investigational Site, West Jordan

GSK Investigational Site, Salt Lake City

GSK Investigational Site, Salt Lake City

GSK Investigational Site, Phoenix

GSK Investigational Site, Mesa

GSK Investigational Site, Mesa

GSK Investigational Site, Chandler

GSK Investigational Site, Tempe

GSK Investigational Site, Albuquerque

GSK Investigational Site, Las Vegas

GSK Investigational Site, San Diego

GSK Investigational Site, Peoria

GSK Investigational Site, San Diego